You are here

Article Text

Article menu
Download PDFPDF
Letter
Postoperative subconjunctival 5-fluorouracil in the management of recurring pterygium
  1. Anupama Pherwani1,
  2. Vipul Vakil2,
  3. Habibullah Eatamadi3,
  4. Ravinder Singh3,
  5. Harminder S Dua3
  1. 1Division of Ophthalmology and Visual Sciences, University of Nottingham, Queens Medical Centre, Nottingham, UK
  2. 2PBMA’S H V Desai Hospital, Pune, India
  3. 3Division of Ophthalmology and Visual Sciences, University of Nottingham, Queens Medical Centre, Nottingham, UK
  1. Correspondence to: Professor H S Dua Division of Ophthalmology, B Floor, Eye ENT Centre, Queens Medical Centre, University Hospital, Nottingham. NG7 2UH, UK; harminder.dua{at}nottingham.ac.uk

https://doi.org/10.1136/bjo.2006.101956

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The treatment of choice for pterygium is surgical excision. Recurrence is the most common undesirable treatment outcome. Surgery and other modalities of treatment including β-irradiation, topical thiotepa, intraoperative and postoperative use of mitomycin C, 5-fluorouracil (5-FU) and daunorubicin, have been described to reduce recurrence.1–9 Multiple surgery is itself a risk factor for recurrence.9 We present a case in which the fourth surgery for recurrent pterygium resulted in further recurrence, which was thwarted by multiple intralesional injections of 5-FU.

    Case report

    A 34-year-old Afro-Caribbean woman was referred to us in October 2004 for the management of recurrent pterygium in the right eye. She had two previous surgeries, the first in 2002 with conjunctival autograft …

    View Full Text

    Footnotes

    • Competing interests: None.

    • Informed consent was obtained for publication of the person’s details in this report.